Welcome to Vglycin Biomanufacturing
Discover how vglycin can revolutionize the treatment of Type 2 Diabetes.
l
o
a
d
i
n
g
In order to better browse the web, it is recommended to use a computer to watch.
Discover how vglycin can revolutionize the treatment of Type 2 Diabetes.
With 537 million people affected today and projections rising, Type 2 Diabetes poses a growing global challenge.
Long-term hyperglycemia will continue to harm the health of diabetic patients, bringing various complications, including retinopathy, kidney disease, neuropathy, macrovascular disease, cardiomyopathy, infection, metabolic dysfunction, etc.
P37, a legume-derived 37 - amino - acid polypeptide, resists GI protease degradation and has an oral hypoglycemic effect. In its family, vglycin has obvious hypoglycemic and pancreas - repairing effects, suitable for type 2 diabetes treatment as a new oral medicine.
Currently, vglycin can only be extracted from soybeans with problems like low yield, complex process, and waste of land resources; thus, to enable more people to benefit from vglycin - related treatment in the future, we plan to construct a vglycin expression vector using the synthetic biology method to increase its expression level.
Our biomanufacturing system aims to make Vglycin accessible, and allow further Vaglicin-based treatment to be furthes explored.